6 [32] G. A. Block, M. S. Persky, M. Ketteler et al., “A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical out- comes studies in nephrology,” Hemodialysis International, vol. 13, no. 3, pp. 360–362, 2009. [33] J. B. Wetmore and L. D. Quarles, “Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?” Nature Clinical Practice Nephrology, vol. 5, no. 1, pp. 24–33, 2009. [34] P. Evenepoel, B. Meijers, L. Viaene et al., “Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1268–1276, 2010. International Journal of Nephrology